Scientists Discover Plant Molecule That Attacks Aggressive Breast Cancer in a Completely New Way.
In the relentless search for new cancer therapies, scientists sometimes find powerful solutions in unexpected places.
A recent study has revealed that a molecule derived from a plant could offer a promising new strategy to combat one of the most aggressive forms of breast cancer.
Researchers studying Munronia henryi, a plant known for producing complex natural compounds called limonoids, have identified a newly discovered molecule named DHL-11 that demonstrates strong activity against triple-negative breast cancer (TNBC).
The findings, published in the journal Acta Pharmaceutica Sinica B, highlight a completely unconventional way of disabling a key cancer enzyme—opening the door to a new generation of targeted therapies.
Why Triple-Negative Breast Cancer Is So Difficult to Treat
Triple-negative breast cancer is considered one of the most challenging breast cancer subtypes. Unlike many other breast cancers, TNBC lacks three key receptors commonly targeted by modern treatments:
-
Estrogen receptors (ER)
-
Progesterone receptors (PR)
-
HER2 protein receptors
Because these therapeutic targets are absent, treatment options are limited, and chemotherapy often remains the primary therapy.
TNBC also tends to grow faster, spread earlier, and recur more frequently than other forms of breast cancer. As a result, scientists worldwide are actively searching for new molecular targets that could offer more effective and precise treatments.
Discovery of a Powerful Natural Compound
While studying the chemical compounds produced by Munronia henryi, researchers isolated two previously unknown prieurianin-type limonoids.
Among them, one compound immediately stood out.
The researchers named it DHL-11, and early experiments revealed that it strongly inhibited the growth of triple-negative breast cancer cells.
Limonoids are natural molecules that plants often produce as part of their chemical defense systems against insects and environmental threats. Interestingly, many such compounds have also shown potential medicinal benefits, including antiviral, anti-inflammatory, and anticancer properties.
DHL-11 appears to be another remarkable example of how nature’s molecular arsenal can inspire modern medicine.
How DHL-11 Attacks Cancer Cells
Laboratory studies showed that DHL-11 affects cancer cells in several ways simultaneously.
When TNBC cells were exposed to the compound, researchers observed:
-
Reduced cancer cell proliferation
-
Decreased migration ability, limiting the potential spread of tumors
-
Cell cycle arrest at the G2/M phase, stopping cell division
-
Induction of apoptosis, the process of programmed cell death
In addition, treated cancer cells accumulated higher levels of reactive oxygen species (ROS). Excess ROS can damage cellular components and overwhelm cancer cells’ repair mechanisms.
The compound also increased DNA damage, pushing cancer cells toward irreversible destruction.
A Completely Different Mechanism of Action
What truly fascinated researchers was how DHL-11 achieved these effects.
Most cancer drugs work by blocking the active site of an enzyme, preventing it from carrying out its function.
However, DHL-11 takes a very different approach.
The compound binds to a non-catalytic pocket on an enzyme called IMPDH2 (inosine monophosphate dehydrogenase 2).
IMPDH2 plays a crucial role in the production of guanine nucleotides, essential building blocks for DNA and RNA. Rapidly growing cancer cells rely heavily on this pathway to sustain their uncontrolled proliferation.
Instead of simply blocking the enzyme’s activity, DHL-11 disrupts the interaction between IMPDH2 and another protein called FANCI, which is involved in DNA repair.
This disruption triggers the degradation of the IMPDH2 protein itself.
As a result:
-
Guanine production decreases
-
Reactive oxygen species increase further
-
DNA damage accumulates
-
Cancer cells lose their ability to survive
This chain reaction creates a multi-layered attack on tumor cells, making DHL-11 particularly intriguing as a therapeutic candidate.
Success in Advanced Cancer Models
To ensure the findings were not limited to laboratory cell cultures, researchers tested DHL-11 in more advanced experimental systems.
Patient-Derived Tumor Organoids
The compound was tested on breast cancer organoids derived directly from patients, which replicate many characteristics of real tumors.
DHL-11 significantly suppressed the growth of organoids with high IMPDH2 expression, suggesting the therapy may be particularly effective in cancers dependent on this pathway.
Animal Studies
The team also conducted experiments using TNBC xenograft models in animals.
The results were encouraging:
-
Tumor growth was significantly reduced
-
Metastasis was suppressed
-
The compound showed favorable biosafety profiles
These findings suggest DHL-11 may have potential as a therapeutic agent with manageable toxicity.
A New Class of Targeted Cancer Therapy?
The discovery positions DHL-11 as a novel IMPDH2 degrader, representing a growing class of therapeutic strategies that do more than simply inhibit proteins.
Instead, they trigger the destruction of disease-causing proteins altogether.
This strategy is gaining increasing attention in drug development because degrading a protein can produce longer-lasting and more comprehensive effects than temporary inhibition.
For patients with IMPDH2-positive triple-negative breast cancer, this could eventually lead to more precise and effective treatment options.
Nature Still Holds Many Medical Secrets
Natural products have historically played a major role in medicine. Many widely used drugs—including antibiotics, anticancer agents, and immunosuppressants—originated from compounds found in plants, fungi, or microorganisms.
The discovery of DHL-11 reinforces a powerful idea:
Nature remains one of the most sophisticated chemical laboratories on Earth.
Plants have spent millions of years evolving complex molecules to defend themselves. Modern science is only beginning to understand how these compounds can be repurposed to fight human diseases.
The Road Ahead
While the results are promising, further studies will be required before DHL-11 can move toward clinical use.
Future research will focus on:
-
Optimizing the molecule for drug development
-
Conducting more extensive safety studies
-
Testing its effectiveness in clinical trials
If these steps prove successful, DHL-11 could eventually become part of a new generation of precision oncology treatments derived from natural compounds.
Conclusion
A simple plant-derived molecule has demonstrated the power to disrupt cancer at its core, not by blocking—but by dismantling its survival machinery.
For aggressive conditions like triple-negative breast cancer, this represents more than progress—it signals a possible shift in treatment philosophy.
By targeting IMPDH2 in a completely unconventional way, DHL-11 opens the door to smarter, more precise therapies.
Its success across cell studies, organoids, and animal models strengthens the hope for real-world application.
Equally important is the reminder that nature still holds untapped answers to some of medicine’s toughest challenges.
As research advances, molecules like DHL-11 could redefine how we approach cancer therapy in the coming decade.
The journey from plant chemistry to patient care is long—but this discovery makes the destination feel closer than ever.
Explore More:
Scientists Discover a Simple Metabolic Trick That Boosts mRNA Therapy Delivery 20-Fold
Implantable Immune Boosters: How Tiny Devices Could Solve Immunotherapy Failure in Solid Tumors
DNA Robots Are Coming: The Invisible Machines That Could Rewrite Medicine
Vitamin B2’s Dark Side: How Riboflavin May Help Cancer Cells Survive Ferroptosis
K M Manohar is an independent Sci-Tech writer and research curator who explains breakthrough discoveries shaping the future of technology.
Discussion